Navigation Links
ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
Date:3/24/2009

fficer. "In addition, this accretive transaction provides us the opportunity to increase our net cash position, further strengthening our already strong balance sheet, and is consistent with our goal of increasing shareholder value."

From time to time, ViroPharma may evaluate additional opportunities for purchases of its common stock or convertible notes, including through open market purchases or individually negotiated transactions.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Certain st
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
2. ViroPharma to Present at Three November Healthcare Conferences
3. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
4. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
5. ViroPharma to Present at Three October Healthcare Conferences
6. ViroPharma to Present at Three September Healthcare Conferences
7. ViroPharma To Acquire Lev Pharmaceuticals
8. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma to Present at Two Upcoming Healthcare Conferences
11. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... New spin-out from Cancer ... Innovation Capital and Johnson & Johnson Development Corporation  ... focused on harnessing the potential of circulating tumour ... treatment, today announced it has raised £4m in ... including Cambridge Innovation Capital and Johnson & Johnson ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... Manchester have generated a new star-shaped molecule made up of ... ever created. , Known as a ,Star of ... over a quarter of a century and the team,s findings ... , Consisting of two molecular triangles, entwined about each other ... tiny each triangle is 114 atoms in length around ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This is ... of the M-Phenylenediamine (mPDA) industry in Global and ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... and Play Capability of MyMedicalRecords Pro to ... Technology Experts Expected at HIMSS09LOS ANGELES, Feb. ... Bulletin Board: FVRL), which through its wholly-owned ... consumer-controlled Personal Health Records ("PHRs") ( www.mymedicalrecords.com ...
... Feb. 24 Particle Sciences Inc. today announced the ... from tissue hydration to the passivation of medical device ... series of patent-pending polymers that allow Particle Sciences to ... PS, Director of New Technologies.Particle Sciences has already used ...
Cached Biology Technology:Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 2MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 4MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 5Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System 2
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... New Rochelle, NY, September 22, 2014Cassava, also known as ... high yields in areas of Africa, Asia, and Latin ... With the availability of novel enzymes and processes designed ... then be used to produce sweeteners such as glucose, ... alternative to corn, as described in a Review article ...
(Date:9/22/2014)... manufacture their own "antifreeze" proteins to survive in ... side effect, researchers report: The protein-bound ice crystals ... when temperatures warm. , The finding is ... Academy of Sciences . , "We discovered what ... evolution of antifreeze proteins in Antarctic notothenioid fishes," ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... for a boat ride or even taken a drink from the ... how valuable? That,s always been a tough question for policy makers ... societal needs that compromise it, such as the need to grow ... so has been greatly enhanced by a new policy-making framework developed ...
... that there are 1.7 million species of animals, plants ... be discovered. Unfortunately, as new species are found, many ... biodiversity. The more diversity there is in a population, ... is key to ecosystem resilience. Disease, destruction of ...
... and decisions to use "least toxic pesticides" and "pesticides ... decade, but according to three scientific organizations the ... Society (APS) and the Plant-Insect Ecosystems Section of the ... not the correct approaches to the pesticide component of ...
Cached Biology News:Study offers new tool for incorporating water impacts into policy decisions 2Persistence or extinction: Through a mathematical lens 2Persistence or extinction: Through a mathematical lens 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 2Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 4Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 5
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known maize ...
... an excellent choice for supporting hydrocarbon processing. In ... this one-channel workhorse can double sample throughput by ... You get all the capability and reliability you ... that has the same proven performance of Agilents ...
... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...
... the six short years since publication of ... Walkers widely acclaimed Protein Protocols Handbook, there ... protein biochemistry. In recognition of the level ... rapid evolution of new methodologies directed to ...
Biology Products: